Korean J Med.  2009 Dec;77(6):780-786.

Metastatic collecting duct (Bellini duct) carcinoma: A case report

Affiliations
  • 1Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. koyoonho@catholic.ac.kr
  • 2Department of Radiology, The Catholic University of Korea College of Medicine, Seoul, Korea.
  • 3Department of Hospital Pathology, The Catholic University of Korea College of Medicine, Seoul, Korea.

Abstract

Renal cell carcinoma accounts for 2.6% of all cancer, and most renal cell carcinoma has a clear cell origin. Bellini duct carcinoma, which arises from collecting duct cells (Bellini cells), is a rare type of renal cell carcinoma, constituting less than 1% of all renal cell carcinoma. The prognosis of Bellini duct carcinoma is very poor, and more than 60% of the patients die within 2 years of diagnosis. There is no consensus regarding the optimal treatment. We report a case of Bellini duct carcinoma in a 53-year-old male with multiple lung and liver metastases. The patient was treated with eight cycles of M-VAC (methotrexate, vincristine, doxorubicin, and cisplatin) combination chemotherapy. The patient currently shows a radiological partial response without disease progression 10 months after the chemotherapy.

Keyword

Collecting duct carcinoma; Neoplasm metastasis; Antineoplastic agents

MeSH Terms

Antineoplastic Agents
Carcinoma, Renal Cell
Consensus
Disease Progression
Doxorubicin
Drug Therapy, Combination
Humans
Liver
Lung
Male
Middle Aged
Neoplasm Metastasis
Prognosis
Vincristine
Antineoplastic Agents
Doxorubicin
Vincristine
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr